海思科(002653.SZ)：HSK39297片上市许可获受理

Core Viewpoint - Company Sichuan Hisun Pharmaceutical Co., Ltd., a subsidiary of Hisun Pharmaceutical (002653.SZ), received a Notice of Acceptance from the National Medical Products Administration for the drug HSK39297 tablets, aimed at treating adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitor therapy [1] Group 1 - The drug HSK39297 is specifically indicated for adult patients with PNH [1] - The acceptance notice was issued on January 6, 2026 [1] - The drug is intended for patients who have not undergone prior treatment with complement inhibitors [1]